Primary ovarian insufficiency (POI) is characterized by the loss of ovarian function before the age of 40 in humans. Although most cases of POI are idiopathic, many are familial, underlying a genetic origin of the disease. Mutations in genes involved in the control of steroidogenesis, such as NR5A1 (SF-1, Steroidogenic Factor 1), CYP17, CYP19A1 (aromatase), StAR (Steroidogenic Acute Regulatory), and the forkhead transcription factor FOXL2 have been associated with different forms of POI. In males, the homeobox transcription factors Dlx5 and Dlx6 are involved in the control of steroidogenesis through the activation of GATA4-induced-StAR transcription. Here, we analyze the potential involvement of Dlx5 and Dlx6 in female reproduction. To this end, we make use of an existing mouse model in which Dlx5 and Dlx6 are simultaneously disrupted. We show that: (i) allelic reduction of Dlx5 and Dlx6 in the mouse results in a POI-like phenotype, characterized by reduced fertility and early follicular exhaustion; (ii) in granulosa cell lines, a reciprocal regulation exists between Dlx5 and Foxl2; (iii) in the mouse ovary, allelic reduction of Dlx5/6 results in the upregulation of Foxl2. We propose that the mutual regulation between Dlx5/6 and Foxl2 and their opposite effects on StAR expression might contribute to determine the homeostatic control of steroidogenesis within the ovary. Dysregulation of this homeostatic control would result in abnormal follicular maturation and reduced fertility. Our results bring new elements to our conceptual model of follicle maturation and maintenance and provide new potential genetic targets for cases of familial POI.
INTRODUCTION
Primary ovarian insufficiency (POI) (1), the early loss of normal ovarian function, can result from different ovarian defects including early decrease in the primordial follicle pool, increased or accelerated follicular atresia, follicle growth blockade or increased follicle exhaustion owing to accelerated maturation. The clinical characteristics of POI are a primary or secondary amenorrhea with elevated levels of circulating gonadotropins like luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and low levels of estradiol.
Although most cases of POI are idiopathic, and few are due to metabolic, autoimmune or iatrogenic causes, compelling evidence suggest that certain forms of the disease have a genetic etiology. Many POI cases are familial (2 -5) and specific genetic alterations or mutations have been associated with syndromic or non-syndromic forms of POI (1) . Although the most frequent anomalies are chromosome X alterations, POI-associated mutations have been also identified in autosomal genes: ATM (mutated in Ataxia Telangiectasia) (6, 7) , FSHR (8), GDF9 (9), NOBOX (10,11), AIRE (12), the Steroidogenic Acute Regulatory gene (StAR) (13) and the forkhead transcription factor FOXL2. In particular, mutations of * To whom correspondence should be addressed at: CNRS UMR7221, Evolution des Régulations Endocriniennes, Muséum National d'Histoire Naturelle, 7 rue Cuvier, 75231 Paris Cedex 05, France. Tel: +33 140793621; Fax: +33 140793618; Email: glevi@mnhn.fr FOXL2, responsible for Blepharophimosis Ptosis Epicanthus inversus Syndrome, a rare syndrome characterized by complex eyelid malformations, have also been associated with POI (14) (15) (16) .
FOXL2 is expressed in the ovary, where it regulates the expression of genes involved in the control of steroidogenesis (17, 18) : it interacts with Steroidogenic Factor-1 (SF-1) and inhibits the expression of both CYP17 (17) and StAR (19) and activates the expression of CYP19A1 (aromatase) (20) , suggesting that its involvement in POI might result from a dysregulation of steroid biosynthesis. StAR-mediated mitochondrial cholesterol transport is the rate-limiting step in steroid biosynthesis and is therefore one of the best targets for the regulation of steroid availability. Among the many transcription factors and signaling pathways involved in the control of StAR, we have recently shown that the homeobox transcription factor Dlx5 activates StAR expression in cooperation with GATA-4 (21) .
Dlx genes comprise a highly conserved family of homeobox genes homologous to the Distal-less (Dll) gene of Drosophila. During embryonic development, Dlx genes are expressed in craniofacial primordia, basal telencephalon and diencephalon, in the distal regions of extending appendages, in differentiating osteoblasts and in Leydig cells.
Deletion of the coding and intergenic regions of Dlx5 and Dlx6 with a single targeting event in the mouse results in perinatal death and in a limb malformation reminiscent of the human ectrodactyly, Split Hand Foot Malformation type I (SHFM1) and in the lower-to-upper jaw transformation (22) (23) (24) .
Besides these patterning defects, these same mutants have also permitted to identify the roles for Dlx5 and Dlx6 in the control of cell differentiation. In particular, Dlx5/6 play a role in the control of bone development (25) and in the differentiation of Leydig cells (21) . Besides both being upstream regulators of StAR, Dlx5/6 and Foxl2 appear to be associated in a common regulatory network. Foxl2 expression is strongly activated in the first pharyngeal arch of Dlx5/6-null embryos indicating that Dlx5/6 are direct or indirect repressors of its expression (26) .
Here, we make use of the same Dlx5/6 mutants to analyze the function of these genes in female reproduction. We show that the allelic reduction of Dlx5 and Dlx6 in the mouse results in a POI phenotype characterized by the rapid depletion of the follicular pool and premature female infertility and that a mutual regulation between Foxl2 and Dlx5 also takes place in the ovary. Our findings suggest a more general implication of Dlx genes in the control of steroidogenesis and reproduction than previously suspected.
RESULTS

Allelic reduction of Dlx5 and Dlx6 results in female subfertility
We have noticed that Dlx5/6 +/2 mice are subfertile. Intercross between heterozygous animals carrying this mutant haplotype backcrossed on the B6D2F1/JRj genetic background rarely resulted in pregnancy. Consequently, the few litters obtained were constituted by a small number of pups and it was almost impossible to obtain homozygous embryos. Therefore, for many years, the Dlx5/6 mutation has been backcrossed on the B6D2F1/N genetic background. To gather information about the reproductive status of mice carrying the Dlx5/6 +/2 haplotype, we analyzed the breeding record of our colony over 10 years (Fig. 1) . First, we analyzed the number of pups per litter.
On the one hand, when crossed with wild-type (WT) females, B6D2-Dlx5/6 +/2 /N males produced the same number of pups (9.17 + 2.28) as males carrying other mutations on the same genetic background (e.g.
B6D2-Dlx5
+/2 /N (9.36 + 2.00)); this value corresponds to the average litter size of B6D2 male mice in our animal facility. We concluded that Dlx5/6 +/2 males were not subfertile. On the other hand, we observed a pronounced reduction in the number of pups per litter of Dlx5/6 +/2 females. Indeed, when Dlx5/6 +/2 females were crossed with B6D2 partners, the litter size was invariably reduced by about 40% independently of other heterozygous mutant alleles carried by the males (Fig. 1 ). This reduction in litter size was highly significant and reproducible (P , 10 25 ). The female subfertility associated with the Dlx5/6 +/2 mutation was also associated with a shorter reproductive age of these mice. Indeed, Dlx5/6 +/2 females produced in average 1.8 litters (n ¼ 31) and most of them carried their last litter no later than at 6 months (22/31) of age; whereas, their WT littermates produced an average of 4.5 litters and in most cases had the last litter after 1 year of age.
This reduced fertility was accompanied by significantly increased levels of LH in 6-month-old Dlx5/6 +/2 females (WT 0.22 + 0.14 ng/ml; Dlx5/6 +/2 0.59 + 0.19 ng/ml; P ¼ 0.019); variations in FSH and estradiol did not reach a level of significance in the sample we analyzed.
Allelic reduction of Dlx5 and Dlx6 results in premature follicular maturation Given the strong female subfertility associated with the Dlx5/6 mutation, we further analyzed the ovarian phenotype of these animals. Histological analysis of 6-month-old mice ovaries revealed an abnormal follicular maturation in Dlx5/6 +/2 mice ( Fig. 2B 
and B
′ ) compared with their WT littermates ( Fig. 2A and A ′ ). Mutant ovaries were smaller and presented a higher number of abnormal follicles containing multiple oocytes ( Fig. 2B and B ′ ). In particular, Dlx5/6 +/2 ovaries had a highly significant reduction in the number of primordial/primary follicles and secondary/pre-antral follicles and a significant increase of antral/pre-ovulatory follicles and corpora lutea (Fig. 2C) . These results indicate a depletion of the follicular pool in Dlx5/6 +/2 mice, which is likely to result from a higher and premature follicular activation.
To better understand the mode of action of Dlx5 and Dlx6 on follicular maturation, we have analyzed their pattern of expression in the mouse ovary and we have compared it with that of Foxl2. Dlx5 immunoreactivity (Fig. 3A , A ′ and A ′′ ) is not detectable in primordial and primary follicles, but is clearly present in the majority of secondary, preantral and antral follicles in granulosa and theca cells (arrows in In situ hybridization with Dlx6- (Fig. 3C ) and Dlx5- (Fig. 3D ) specific probes (24) resulted in a pattern of expression similar to that obtained with anti-DLX5 antibodies, showing high levels of expression in secondary, preantral and antral follicles (II and III in Fig. 3C ) and very low levels in primary and primordial follicles (arrowheads in Fig. 3D ).
Both at the protein and at the mRNA level, the pattern of Dlx5/6 and Foxl2 distribution (28) during follicular maturation is partially overlapping in the granulosa of mature follicles and is to a large extent complementary in earlier follicles and in theca cells suggesting a possible mutual regulation.
Reciprocal regulation between Dlx5/6 and Foxl2 in granulosa cells
In the first pharyngeal arch mesenchyme of the early mouse embryo, Dlx5 and Dlx6 are repressors of Foxl2 (26). To explore if a similar regulation could be found also in adult ovarian granulosa cells, we simultaneously transfected KGN human granulosa-like cells (29) with: (i) a reporter construct (pFoxL2-luc, Fig. 4A ) in which the luciferase gene is under the control of the FoxL2 promoter and (ii) an expression vector for either FOXL2 or Dlx5. In agreement with the previously published data (30 -32), FOXL2 was a strong activator of pFoxL2-luc ( Fig. 4C ; P ¼ 10
27
). Conversely, co-transfection of pFoxL2-luc and the Dlx5 expression vector resulted in a significant decrease in the pFoxL2-luc expression ( Fig. 4D ; P ¼ 7 × 10
25
) when compared with the endogenous activation of pFoxL2-luc in KGN cells. A similar regulation was found when identical experiments were repeated on the COV434 granulosa cell line (data not shown). These data suggest that Dlx5 is a transcriptional repressor of FOXL2 also in adult granulosa cells. Inspection of the pFoxL2-luc construct revealed the presence of a putative Dlx response element at position 2860 (Fig. 4A) . To explore the possibility that this response element is involved in FOXL2 repression by Dlx5, we generated two truncated variants of the pFoxL2-luc vector (p-704-luc and p-527-luc), which did not include the putative Dlx5-binding element (Fig. 4A) . The Dlx5-mediated inhibition was maintained on both constructs (Fig. 4D) suggesting an indirect action of Dlx5. As expected, p-527-luc, which lacked the two major FOXL2-responsive elements at 2579 and 2569 (32), lost the capacity to be activated by FOXL2 (P ¼ 0.85; Fig. 4C ). However, its basal level of expression was still significantly reduced by Dlx5 (P ¼ 9 × 10
23
; Fig. 4D ). Similar results were obtained in KGN and COV434 granulosa cell lines.
To explore the possibility that FOXL2 could exert a reciprocal regulation on the expression of Dlx5/6, we co-transfected KGN cells with reporter vectors in which the luciferase gene is under the regulation of two well-known Dlx5/6 intragenic enhancers (p-mI56i-luc and p-mI56ii-luc; Fig. 4B ) and a FOXL2 expression vector. FOXL2 could activate significantly the expression level of both reporters (p-mI56i-luc: P ¼ 10
; p-mI56ii-luc: P ¼ 9 × 10
26
) suggesting that it can act as an activator of Dlx5/6 (Fig. 4E ).
Foxl2 regulation in Dlx5/6 1/2 ovaries
To test whether Dlx5/6 allelic reduction results in the regulation of Foxl2 in vivo, we performed in situ expression analyses on Dlx5/6 +/2 ovaries (Fig. 5) . As already seen at the protein level (Fig. 3B) , in WT ovaries, Foxl2 is expressed in granulosa cells at all stages of follicle maturation. However, its expression decreases during follicular maturation ( Fig. 5B  and E) . In primary and secondary follicles, we could not detect any difference in the level of Foxl2 expression between WT and Dlx5/6 +/2 ovaries ( Fig. 5B and C) . On the same sections, however, the Foxl2 in situ hybridization signal was clearly more intense in the antral follicles of Dlx5/6 +/2 animals ( Fig. 5E and F) , indicating its upregulation at late stages of follicular maturation in a mutant background.
DISCUSSION
In this study, we have shown that allelic reduction of Dlx5 and Dlx6 in the mouse results in reduced female fertility characterized by smaller litter size and premature reproduction arrest. Histological analysis of Dlx5/6 +/2 ovaries reveals a premature follicular depletion. As FSH and LH levels are not decreased in Dlx5/6 +/2 mice, the reduced fertility could be interpreted as a form of POI.
In humans, POI is characterized by at least 6 months of amenorrhea, sex steroid deficiency and high serum concentrations of FSH before the age of 40. Our mouse model presented a similar subfertility profile, but hormonal levels and ovarian histology were analyzed before the arrest of the reproductive period. The rapid depletion of the follicular pool and the increased levels of LH are compatible with certain POI phenotypes observed in other mouse models (1, 33) .
One of the genes responsible for autosomal familial cases of syndromic POI is the forkhead transcription factor FOXL2. In humans, FOXL2 is one of the earliest known markers (27) of ovarian differentiation and plays a role at an early stage of ovarian development. FOXL2 is also strongly expressed in postnatal and adult follicular cells and is involved in ovarian development and/or maintenance during all female fertile life (28) . Indeed, recently, by conditional inactivation of Foxl2 in the mouse, it has been shown that Foxl2 is required to prevent transdifferentiation of an adult ovary to a testis (34) . Foxl2-targeted inactivation in adult ovarian follicles results in reprogramming of granulosa and theca lineages into Sertolilike and Leydig-like cell lineages.
As Dlx5/6 are suppressors of Foxl2 during mouse embryonic craniofacial development (26), we have verified if a similar regulation was present also in the ovary. In vitro, our results suggest that a reciprocal regulatory loop might exist between FOXL2 and Dlx5: Dlx5 inhibits the expression of FoxL2, whereas the latter activates both its own transcription and that of Dlx5/6. In vivo, this finding was mirrored by an increase in Foxl2 expression in Dlx5/6 +/2 ovaries. Our results suggest that a reciprocal regulatory loop might exist between Foxl2 and Dlx5/6 during folliculogenesis (Fig. 6) . Foxl2 is strongly expressed in primordial and primary follicles but its expression decreases during follicle maturation. High levels of Foxl2 are present in primordial and primary follicles, whereas Dlx5 is not detected (Fig. 3 and Fig. 6, upper panel) . We have shown that FOXL2 can activate the expression of Dlx5/6 in granulosa cells. It is therefore possible that, during early stages of follicular maturation, Foxl2 initiates the expression of Dlx5/6. In secondary follicles, Dlx5 and Dlx6 are co-expressed with Foxl2 in granulosa cells and could be involved in its downregulation (Fig. 6, middle  panel) . Finally, in mature antral follicles, Dlx5 and Dlx6 are highly expressed. Allelic reduction of Dlx5 and Dlx6 results in an accelerated follicular maturation and in premature follicular exhaustion. We find a higher level of Foxl2 expression in antral follicles of mutant ovaries, which could be explained by a partial reduction of the Dlx5/6-dependent inhibition (Fig. 6, lower panel) . Indeed, the ovarian phenotype observed in our mouse model is the opposite of that observed in Foxl2 2/2 mice, where follicles are blocked at primordialprimary transition (28) . Similarly, in POI patients carrying FOXL2 mutations, follicles often fail to undergo maturation (35) . The cooperation between Dlx5/6 and Foxl2 might also affect the process of steroidogenesis. We have previously shown that Dlx5/6 are expressed in fetal Leydig cells during mouse testis development, their double homozygous inactivation leads to decreased testosterone levels and to an abnormal masculinization phenotype. The mechanism through which Dlx5 regulates steroidogenesis involves a GATA-4-dependent activation of StAR (21). Foxl2 might also be involved in the regulation of StAR as an indirect inhibitor (19) . These findings suggest that the mutual regulation between Dlx5/6 and Foxl2 and their opposite effects on StAR expression might contribute to determine the homeostatic control of steroidogenesis within the ovary. Dysregulation of this homeostatic control would result in abnormal follicular maturation and reduced fertility. As Dlx5/6 homozygous mutants die at birth, further studies on conditional and inducible mouse mutants will permit to better elucidate the regulatory network involving Dlx5/6 and Foxl2.
Our results provide new candidate genes to better understand the genetic bases of POI and, more generally, of follicle maturation and maintenance. The Dlx5/6 locus becomes a natural target to search for POI-associated mutations; this same locus has been previously associated with SHFM (22); however, no mutation has been identified in the coding region of these genes suggesting a regulatory defect (36, 37) . As POI is not associated with limb or craniofacial defects ascribable to Dlx5/6, it is likely that an ovary-specific enhancer is involved.
MATERIALS AND METHODS
Animals
Animal procedures were approved by National and Institutional ethical committees. Dlx5 and Dlx5/6 mutant mice were genotyped as previously described (22, 24, 38) . DNA was extracted from mice tails using a lysis buffer (sodium hydroxide) and neutralized with a neutralization buffer (Tris -HCl and ethylene diaminetetraacetic acid). Animals were backcrossed with WT B6D2F1/JRj females purchased from Elevage Janvier (France) or with WT B6D2F1/N from Charles River Laboratory (Italy). The relative fertility of Dlx5/6 +/2 heterozygous mutants was determined by analyzing the record of over 10 years of crossings of these animals (about 36 generations) performed in the animal facility of the Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy.
Histological analysis
Ovaries of 6-month-old mice were fixed overnight (O/N) in Bouin's fixative (Sigma, France) at 48C. Samples were then dehydrated with ethanol and Safe Solv (Labonord, France) and embedded in paraffin. Serial 8 mm sections of the whole ovary were stained by Mallory Trichromic protocol [Groat's hematoxylin, acid fuchsin, aniline blue/orange G (39)]. We prepared a complete set of parasagittal serial sections of each ovary analyzed. Follicles were counted from three nonadjacent sections roughly positioned in the central part of each ovary using an optical microscope (Olympus). Secondary and antral follicles were visualized using a 20X objective, primordial and primary follicles with an oil-immersion 100X objective. All the surface of each section was inspected blindly to the genotype for the presence of follicles and the total number of follicles per section was considered.
In situ hybridization
Ovaries of 6-month-old mice were dissected in phosphatebuffered saline (PBS), fixed overnight in 4% formaldehyde at 48C, then cryoprotected by immersion in sucrose 15% then 30% in PBS before mounting on Tissue-Tek. Superfrost Ultra Plus slides (Menzel-Gläser) were used to collect 8 mm cryosections and stored at 2808C before further use.
Gene expression was analyzed by in situ hybridization using digoxigenin (DIG)-UTP-labeled antisense RNA probes against Dlx5, Dlx6 (40) and Foxl2. After hybridization, probes were detected using an alkaline-phosphatase-conjugated anti-DIG antibody and BM Purple substrate (Roche).
Immunohistochemistry
Paraffin sections of 8 mm were used for immunodetection using anti-FOXL2 directed against the C-terminal region (1/350) (27) and anti-DLX5 (1/500) antibodies (no. HPA005670, Sigma).
Slides were rehydrated and endogenous peroxidases were inactivated by 2% H 2 O 2 treatment for 15 min. Antigen retrieval was performed in citrate buffer (1.8 mM citric acid, 8.2 mM sodium citrate, pH 6.0) by microwave heating for 5 min twice (650 W); non-specific sites were blocked with PBS containing 10% fetal calf serum (FCS) (Sigma). Primary antibodies were diluted in PBS containing 1% FCS and incubated overnight at 48C. Immunodetection was carried out following manufacturer's instructions (no. K4010, Dako).
Hormonal dosage
Blood was collected from 6-month-old mice in heparin tubes. Plasma was separated by centrifugation and stored at 2208C.
Circulating levels of LH, FSH (ImmunoDiagnostic System nos CL-AHR002 and CL-AHR004) and estradiol (Beckman no. DSL-4800) were measured by radioimmunoassay.
Statistical analyses were performed using non-parametric Mann -Whitney test.
Plasmids and expression vectors
Human FOXL2 ORF was cloned into pcDNA3.1-topoTA cloning vector (Invitrogen, CA, USA) driven by a cytomegalovirus promoter (41) and sequenced. Murine Dlx5 cDNA was amplified by polymerase chain reaction (PCR) and cloned in pCS2 + MT using BamH1 restriction enzyme.
pFoxL2-luc was obtained, containing the 2893/+178 caprine FoxL2 promoter driving the luciferase expression. The FoxL2 promoter was obtained by PCR and inserted in pGL3-basic vector (Promega, Madison, WI, USA) after Kpn1/Xho1 enzyme digestion (20) . The promoter fragment 2704/+178 was obtained by digestion of pFoxL2-luc with, respectively, Kpn1/Mlu1 restriction. The -527/+178 promoter fragment was obtained by PCR using pFOXL2-luc vector as the matrix.
p-mI56i-luc and p-mI56ii-luc plasmids are pGL4-24 (Promega) vectors in which the Dlx5/6 intragenic conserved enhancers [i and ii, (42) ] have been cloned upstream of a minimal promoter driving luciferase expression.
Cell culture and transfection
Human granulosa cells lines [KGN (29) or COV434 (43)] were grown in DMEM-F12 medium, supplemented with 10% FCS and 1% penicillin/streptomycin (Invitrogen, CA, USA). Cells were seeded in 24-well plates 12 h before transfection at a density of 4 × 10 4 cells/cm 2 . For transfection, the calcium-phosphate method was used (44) .
Luciferase assays
Reporter assays were performed using the Dual-Luciferase Reporter Assay System (Promega). A Renilla luciferase vector (pRL-RSV, Promega) was co-transfected to monitor transfection efficiency. For each replicate, the firefly activity observed was divided by the activity recorded from Renilla luciferase vector. Luminescence was measured using Berthold LB941 multimode reader TriStar and analyzed with Mikrowin version 4.3x software.
KGN or COV434 cells were cotransfected with 570 ng of luciferase reporter vector (pFoxL2-luc or its truncated variants, p-mI56i-luc, p-mI56ii-luc), 400 ng of inducer vector (empty vector, FOXL2 or Dlx5 expression vectors) and 30 ng of Renilla pRL-RSV control vector.
For each experiment, luciferase activity was measured on six biologically independent replicates of either KGN or COV434 cells. Relative luciferase units represent mean values obtained from independent replicates and are the ratio of firefly luciferase activity over Renilla luciferase activity in the samples. Statistical significance was estimated by a Student's t-test. 
